RET and neoplasm: Compared with these other molecular subtypes, RET+ patients had a higher frequency of neuroendocrine histology (RET+ versus ALK+: 12% vs. 2%, p = 0.025; RET+ vs. ROS1+: 12% vs. 0%, p = 0.010) as well as peripheral primary tumours (RET+ vs. ALK+: 69% vs. 47%, p = 0.029; RET+ vs. ROS1: 69% vs. 36%, p = 0.003).